NY-ESO-1 Antibody (Rabbit mAb) [D2K7]

Catalog No.: F4630

    Application: Reactivity:
    • Lane 1: HT-1080, Lane 2: U266
    1/

    当該製品は品切れ状态で、メールアドレスをご教示いただければ、お客様に返信いたします。

    代表番号: 045-509-1970|電子メール:sales@selleck.co.jp

    キーポイント

    WB
    転写条件(ウェット): 200 mA, 60 min,Recommended to use 0.22 μm PVDF 膜の使用をお勧めします。
    60秒以上の露光(暴露)を推奨します。

    使用情報

    Dilution
    1:1000
    1:100
    1:1600
    1:400
    Application
    WB, IP, IF, FCM
    Source
    Rabbit Monoclonal Antibody
    Reactivity
    Human
    Storage Buffer
    PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3
    Storage (from the date of receipt)
    -20°C (avoid freeze-thaw cycles), 2 years
    Predicted MW Observed MW
    18 kDa 20 kDa (monomer), 40 kDa (dimer)
    *なぜ予測分子量と実際の分子量が異なるのか?
    下記の原因により、実際の分子量が予測と異なる:タンパク質の翻訳後修飾(リン酸化/糖鎖付加),スプライシングバリアント,イソフォーム,相対的な電荷,ポリマー。
    ポジティブコントロール U266 cells; HT‑1080 cells; NCI‑H1299 cells; H929 cells; U266‑B1 cells
    ネガティブコントロール HeLa cells; Jurkat cells

    プロトコール

    WB
    Experimental Protocol:
     
    Sample preparation
    1. Tissue: Lyse the tissue sample by adding an appropriate volume of ice-cold RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail),and homogenize the tissue at a low temperature or lyse it by sonication on ice, then incubate on ice for 30 minutes.
    2. Adherent cell: Aspirate the culture medium and wash the cells with ice-cold PBS twice. Lyse the cells by adding an appropriate volume of RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail) , sonicate to lyse the cells, and incubate on ice for 30 minutes.
    3. Suspension cell: Transfer the culture medium to a pre-cooled centrifuge tube. Centrifuge and aspirate the supernatant. Wash the cells with ice-cold PBS twice. Lyse the cells by adding an appropriate volume of RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail) , sonicate to lyse the cells, and incubate on ice for 30 minutes.
    4. Place the lysate into a pre-cooled microcentrifuge tube. Centrifuge at 4°C for 15 min. Collect the supernatant;
    5. Remove a small volume of lysate to determine the protein concentration;
    6. Combine the lysate with protein loading buffer. Boil 20 µL sample under 95-100°C for 5 min. Centrifuge for 5 min after cool down on ice.
     
    Electrophoretic separation
    1. According to the concentration of extracted protein, load appropriate amount of protein sample and marker onto SDS-PAGE gels for electrophoresis. Recommended separating gel (lower gel) concentration: 10%. Reference Table for Selecting SDS-PAGE Separation Gel Concentrations
    2. Power up 80V for 30 minutes. Then the power supply is adjusted (110 V~150 V), the Marker is observed, and the electrophoresis can be stopped when the indicator band of the predyed protein Marker where the protein is located is properly separated. (Note that the current should not be too large when electrophoresis, too large current (more than 150 mA) will cause the temperature to rise, affecting the result of running glue. If high currents cannot be avoided, an ice bath can be used to cool the bath.)
     
    Transfer membrane
    1. Take out the converter, soak the clip and consumables in the pre-cooled converter;
    2. Activate PVDF membrane with methanol for 1 min and rinse with transfer buffer;
    3. Install it in the order of "black edge of clip - sponge - filter paper - filter paper - glue -PVDF membrane - filter paper - filter paper - sponge - white edge of clip";
    4. The protein was electrotransferred to PVDF membrane. ( 0.22 µm PVDF membrane is recommended )Reference Table for Selecting PVDF Membrane Pore Size Specifications
    Recommended conditions for wet transfer: 200 mA, 60 min.
    ( Note that the transfer conditions can be adjusted according to the protein size. For high-molecular-weight proteins, a higher current and longer transfer time are recommended. However, ensure that the transfer tank remains at a low temperature to prevent gel melting.)
     
    Block
    1. After electrotransfer, wash the film with TBST at room temperature for 5 minutes;
    2. Incubate the film in the blocking solution for 1 hour at room temperature;
    3. Wash the film with TBST for 3 times, 5 minutes each time.
     
    Antibody incubation
    1. Use 5% skim milk powder to prepare the primary antibody working liquid (recommended dilution ratio for primary antibody 1:1000), gently shake and incubate with the film at 4°C overnight;
    2. Wash the film with TBST 3 times, 5 minutes each time;
    3. Add the secondary antibody to the blocking solution and incubate with the film gently at room temperature for 1 hour;
    4. After incubation, wash the film with TBST 3 times for 5 minutes each time.
     
    Antibody staining
    1. Add the prepared ECL luminescent substrate (or select other color developing substrate according to the second antibody) and mix evenly;
    2. Incubate with the film for 1 minute, remove excess substrate (keep the film moist), wrap with plastic film, and expose in the imaging system. (Exposure time of at least 60s is recommended)
    IF
    Experimental Protocol:
     
    Sample Preparation
    1. Adherent Cells: Place a clean, sterile coverslip in a culture dish. Once the cells grow to near confluence as a monolayer, remove the coverslip for further use.
    2. Suspension Cells: Seed the cells onto a clean, sterile slide coated with poly-L-lysine.
    3. Frozen Sections: Allow the slide to thaw at room temperature. Wash it with pure water or PBS for 2 times, 3 minutes each time.
    4. Paraffin Sections: Deparaffinization and rehydration. Wash the slide with pure water or PBS for 3 times, 3 minutes each time. Then perform antigen retrieval.
     
    Fixation
    1. Fix the cell coverslips/spots or tissue sections at room temperature using a fixative such as 4% paraformaldehyde (4% PFA) for 10-15 minutes.
    2. Wash the sample with PBS for 3 times, 3 minutes each time.
     
    Permeabilization
    1.Add a detergent such as 0.1–0.3% Triton X-100 to the sample and incubate at room temperature for 10–20 minutes.
    (Note: This step is only required for intracellular antigens. For antigens expressed on the cell membrane, this step is unnecessary.)
    Wash the sample with PBS for 3 times, 3 minutes each time.
     
    Blocking
    Add blocking solution and incubate at room temperature for at least 1 hour. (Common blocking solutions include: serum from the same source as the secondary antibody, BSA, or goat serum.)
    Note: Ensure the sample remains moist during and after the blocking step to prevent drying, which can lead to high background.
     
    Immunofluorescence Staining (Day 1)
    1. Remove the blocking solution and add the diluted primary antibody.
    2. Incubate the sample in a humidified chamber at 4°C overnight.
     
    Immunofluorescence Staining (Day 2)
    1. Remove the primary antibody and wash with PBST for 3 times, 5 minutes each time.
    2. Add the diluted fluorescent secondary antibody and incubate in the dark at 4°C for 1–2 hours.
    3. Remove the secondary antibody and wash with PBST for 3 times, 5 minutes each time.
    4. Add diluted DAPI and incubate at room temperature in the dark for 5–10 minutes.
    5. Wash with PBST for 3 times, 5 minutes each time.
     
    Mounting
    1. Mount the sample with an anti-fade mounting medium.
    2. Allow the slide to dry at room temperature overnight in the dark.
    3. Store the slide in a slide storage box at 4°C, protected from light.
     

    Datasheet & SDS

    生物学的記述

    Specificity
    NY-ESO-1 Antibody (Rabbit mAb) [D2K7] detects endogenous levels of total NY-ESO-1 protein.
    タンパク質の局在
    細胞質
    Uniprot ID
    P78358
    Clone
    D2K7
    Synonym(s)
    Autoimmunogenic cancer/testis antigen NY-ESO-1, cancer antigen 3, CTAG, CTAG1, CTAG1A, CTAG1B, CTG1B, ESO1, L antigen family member 2, LAGE-2, LAGE2, LAGE2A, LAGE2B, New York esophageal squamous cell carcinoma 1, NY-ESO-1
    Background
    NY‑ESO‑1 is an X‑linked cancer–testis antigen that belongs to a family of germ cell–restricted proteins whose expression is largely confined to testis and ovary under physiological conditions and is absent from most normal somatic tissues while being re‑expressed in a broad spectrum of malignancies. The protein is a relatively small, non‑enzymatic, intracellular antigen with a central repetitive region and more conserved N‑ and C‑terminal portions that provide multiple peptide epitopes efficiently processed and presented by MHC class I and class II molecules, supporting robust CD8⁺ and CD4⁺ T‑cell recognition as well as antibody responses in cancer patients. NY‑ESO‑1 expression arises during fetal testis development and persists in adult germ cells, consistent with a role in gametogenesis, and in tumors its expression is tightly linked to DNA hypomethylation and chromatin changes at the CTAG1B locus, which convert a normally epigenetically silenced gene in somatic lineages into a tumor‑associated antigen. Within tumor cells, NY‑ESO‑1 localizes predominantly to the cytoplasm with variable nuclear staining, and its peptide fragments generated by the proteasome enter the endogenous antigen processing pathway and load onto HLA‑A, -B, or -C molecules, including well‑characterized epitopes such as HLA‑A*02:01–restricted NY‑ESO‑1 157–165, that are recognized by high‑affinity T‑cell receptors. Expression of NY‑ESO‑1 has been documented in a wide range of solid and hematologic tumors, including melanoma, non‑small cell lung carcinoma, ovarian cancer, synovial sarcoma, myxoid liposarcoma, multiple myeloma, and others, often with higher prevalence in advanced or poorly differentiated disease and with enrichment in particular histologic subtypes such as myxoid/round cell liposarcoma and myxoid soft tissue tumors. Tumor expression of NY‑ESO‑1 frequently coincides with spontaneous humoral and cellular immunity, with many patients exhibiting high‑titer NY‑ESO‑1–specific antibodies together with NY‑ESO‑1–specific CD8⁺ and CD4⁺ T cells, underscoring the strong intrinsic immunogenicity of this antigen and its capacity to break tolerance. NY‑ESO‑1 therefore functions as a prototypic target antigen for multiple immunotherapy platforms, including peptide vaccines, recombinant viral or protein vaccines, dendritic cell vaccines, and adoptive T‑cell therapies using TCR‑engineered or naturally expanded NY‑ESO‑1–specific T cells, where NY‑ESO‑1 provides both the tumor‑restricted antigenic determinant and, in some formulations, contributes adjuvant‑like properties through induction of strong helper and cytotoxic responses.
    References

    技術サポート

    ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

    Handling Instructions

    他に質問がある場合は、お気軽にお問い合わせください。

    * 必須

    大学・企業名を記入してください
    名前を記入してください
    電子メール・アドレスを記入してください 有効なメールアドレスを入力してください
    お問い合わせ内容をご入力ください